Recent News

Atsena Therapeutics Process Development Opportunity

October 21, 2021
The Chase Group is pleased to announce their continued partnership with Atsena Therapeutics after being retained to execute a search for an Associate Director/Director of… Continue Reading →

Arcturus Retains The Chase Group to Expand Vaccine Development Programs

October 19, 2021
As part of its growth strategy, Arcturus Therapeutics has partnered with The Chase Group to build and expand their vaccines development team. Founded in 2013… Continue Reading →

The Chase Group Secures SVP, Regulatory for Atsena Therapeutics in Impressive Timeframe

September 8, 2021
After a comprehensive executive search that was completed in less than six weeks, The Chase Group is pleased to announce the placement of Dr. Molly… Continue Reading →

The Chase Group Retained to Identify Vice President, Manufacturing/Supply Chain

September 3, 2021
Ventria Bioscience has partnered with The Chase Group to continue building its leadership team. The company’s technology is time-proven, with more than ten years of… Continue Reading →

Successful Collaboration Results in VP Finance Placement at Ionis

September 2, 2021
The Chase Group (TCG) is pleased to announce the successful recruitment of James Haney as the Vice President of Finance at Ionis Pharmaceuticals. Haney joins… Continue Reading →

Alexza Pharmaceuticals Partnership Continues with Quality Assurance Leadership Search

August 4, 2021
Alexza Pharmaceuticals continues to partner with The Chase Group to secure a Senior Director/Head, Quality Assurance. The Chase Group is currently seeking quality assurance professionals… Continue Reading →

Atsena Therapeutics Retains The Chase Group to Identify Head of Regulatory

July 28, 2021
Atsena Therapeutics has retained The Chase Group to identify a Head of Regulatory. Chase is proud to partner with this clinical-stage ocular gene therapy company… Continue Reading →

Ventria Continues Partnership With The Chase Group to Find Agronomy Operations Leader

July 27, 2021
Ventria Bioscience has partnered once again with The Chase Group to continue building their leadership team as they develop and commercialize innovative medicines with an… Continue Reading →

The Chase Group Secures Teng Jin Ong for Genmab

May 28, 2021
Amid an era of rapid growth, Genmab retained The Chase Group to secure a new clinical development medical executive as they work to pioneer the… Continue Reading →

Ventria Bioscience Cuts to The Chase!

May 6, 2021
Ventria Bioscience is embarking on a path of accelerated growth as they work to double their capacity for multiple products this year. As part of… Continue Reading →
Copyright © 1993-2024 The Chase Group. All Rights Reserved.